The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Webcasts

Webinar Date/Time: Tue, Apr 16, 2024 11:00 AM EDT




QbD Approach to Small-Scale Studies to Enable Rapid Spray Drying Scale-Up

Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT




Mastering QbD for Successful Process Validation Campaigns and Commercial Manufacturing of Biologics

Articles

AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion 

Feliza Mirasol is the science editor for 

CDMO White Raven aims to reduce contamination risk and gain the capability to handle multiple product formats with the installation of Cytiva’s SA25 Aseptic Filling Workcell.

White Raven to Increase Manufacturing Efficiency with Cytiva’s Aseptic Filling Workcell

Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT




UpTempoSM Antibody: A Streamlined Platform Process to Accelerate Biotherapeutics from Gene to Clinic

FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.

FDA Greenlights Orchard Therapeutics' Gene Therapy for Children's MLD; AGC Biologics Selected for Manufacturing

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Cellares CEO Fabian Gerlinghaus discusses the nuts and bolts of counterflow centrifugal elutriation and electroporation innovations and optimization, while hinting at big news on future release testing of products, as a product itself.

Cellares Cell Shuttle is More Valuable Than the Sum of the Value of the Individual Parts

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

Misalignment around liquid filtration requirements and contamination control assurance still persist despite the revisions to Annex 1.

Filtration Clarification Needs in Annex 1

Ramesh Raju Mavuleti*, rrajum@gmail.com, is head of operations, Validation Services India, at Merck Life Sciences Pvt, Ltd.

K. Vasantakumar Pai, PhD , is professor and chairman, PG Department of studies & research in Industrial Chemistry, Kuvempu University

K. Sreedhara Ranganath Pai, PhD, is professor, epartment of Pharmacology, Manipal Academy of Higher Education

Subhasis Banerjee, PhD, is principal technical application expert, Bioprocessing APAC, at Merck Life Sciences Pvt, Ltd.

Somasundaram Gopalakrishnan, is senior consultant, Global Biopharm Center of Excellence, Merck Pte. Ltd.

Tathagata Ray is Area Manager, Process Development at Millipore India Pvt. Ltd (India).